KI-67 PROLIFERATING INDEX AND HISTOLOGICAL GRADE, TYPE AND STAGE OF COLORECTAL CARCINOMA
AbstractBackground: The objective of this study was to assess the relationship of histological type, grade andstage of colorectal carcinoma with proliferative activity as measured by Ki-67 LI. It was a descriptivestudy and conducted at the Department of Pathology, University of Health Sciences, Lahore. Methods:Ki-67 is a protein associated with cell proliferation and is expressed in all the phases of cell cycle exceptG0. In the present study, Ki-67 expression in 50 patients with colorectal adenocarcinomas was observedusing immunohistochemistry with monoclonal antibody MIB-1. Results: Ki-67 LI was high in well andmoderately differentiated adenocarcinomas (mean Ki-67 LI 392.50± 56.58 and 342.24±96.84respectively) as compared to poorly differentiated adenocarcinomas (mean Ki-67 LI 250.00±113.46). Ki-67 LI was high in non mucinous adenocarcinomas than mucin secreting and signet ring celladenocarcinomas (mean Ki-67 393.93±55.91 vs 220.00±49.72 and 200.00±79.05 respectively). As regardthe Dukes’ staging, Ki-67 LI was high in colorectal carcinomas in Dukes’ stage B than tumours in Dukes’stage C (Mean Ki-67 LI 360.13±90.03 vs 241.66±101.31 respectively). Conclusion: The proliferativeactivity as measured by Ki-67 antibody is related to histological type, grade and stage.Keywords: Colorectal carcinoma, Grade, Proliferation index, Immunohistochemistry, Ki-67
Bisgaard LM. Young age colorectal cancer and identification
of hereditary non-polyposis colorectal cancer cohorts. Br J
J Ayub Med Coll Abbottabad 2008;20(4)
Reza MM, Blasco AJ, Andradas E, Cantero R, Mayol J.
Systematic review of laparoscopic versus open surgery for
colorectal cancer. Br J Surg 2006;93:921–8.
Skjelbred F C, Sæbø M, Hjartaker A, Grotmol T, Hansteen LI,
Tveit MK, et al. Meat, vegetables and genetic polymorphisms
and the risk of colorectal carcinoma and adenomas. BMJ
Soreide K, Janssen MAE, Soiland H, Korner.H, Baak APJ.
Microsatellite instability in colorectal cancer. Br J Surg
Conlin A, Smith G, Carey A. F, Wolf R. C, Steele CJR. The
prognostic significance of K-ras, p53, and APC mutations in
colorectal carcinoma. Gut 2005;54:1283–86.
Leslie A, Carrey FA, Pratt NR, Steele RJC. The colorectal
adenoma_carcinoma sequence. Br J Surg 2002;89:845–60.
Rosai J. Gastrointestinal tract In: Ackerman’s surgical
pathology. 9th ed. St. Louis: Mosby, 2004;p. 750–858.
Raraty MG, Winstanley JH. Variation in the staging of
colorectal carcinomas: a survey of current practice. Ann R Coll
Surg Engl 1998;80:188–91.
Gordon PH, Nivatvongs S. editors. Principles and practice of
surgery for the colon, rectum and anus. Missouri: Karen
Oshima FTC, Iriya K, Forones MN. Ki-67 as a prognostic
marker in colorectal cancer but not in gastric cancer. Neoplasm
Urruticocechea A, Smith EI, Dowsett M. Proliferation Marker
Ki-67 in Early Breast Cancer. J Clin Oncol 2005;23:7212–20.
Bancroft J, Anderson G. Tissue Processing and Microtomy
including Frozen. In: Bancroft JD, Gamble M, editors. Theory
and practice of Histological techniques.5th ed. New York:
Churchill Livingstone, 2002; p. 85–107.
Key M. Immunohistochemical Staining Methods, 4th ed.
Avaiable from: http://pri.dako.com/08002_25may06_ihc_
Saleh HA, Jackson H, Khatib G, Banerjee M. Correlation of
bcl-2 Oncoprotein Immunohistochemical Expression with
Proliferation Index and Histopathologic Parameters in
Colorectal Neoplasia. AppI Immunohistochem Mol Morphol
Valera. V, Yokoyama. N, Walter. B, Okamoto. H, Suda.T and
Hatakeyama. K. Clinical significance of Ki-67 proliferation
index in disease progression and prognosis of patients with
resected colorectal carcinoma.Br J Surg 2005;92:1002–7.
Ishida H, Sadahiro S, Suzuki T, Ishikawa K, Kamijo A, Tajima
T et al. Proliferative, infiltrative and metastatic activities in
colorectal tumours assessed by MIB-1 antibody. Oncology
Lanza G Jr, Cavazzini L, Borghi L, Ferretti S ,Buccoliero F and
Rubbini M. Immunohistochemical assessment of growth
fraction in colorectal adenocarcinomas with monoclonal
antibody Ki-67. Relation to clinical and pathological variables.
Path Res Prac 1990;186:608–18.
Georgescu VC, Saftoiu A, Georgescu CC, Ciurea R, Ciurea T.
Correlation of Proliferation Markers, p53 expression and
Histological Findings in Colorectal carcinomas. J gastroenterol
and liver diseases 2007;16:125–9.
Jansson A, Sun XF. Ki-67 expression in relation to
clinicopathological variables and prognosis in colorectal
Shepherd AN, Richman IP, England J. Ki-67 derived
proliferative activity in colorectal adenocarcinoma with
prognostic correlations. J Pathol 1988;155:213–9.
Kyzer S, Gordon HP. Determination of proliferative activity in
colorectal carcinoma using monoclonal antibody Ki-67. Dis
Colon Rectum 1997;40:322–5.
Sahin AA, Ro JY, Brown RW, Ordonez NG, Cleary KR, el
Naggar AK, Assessment of Ki-67 derived tumour
proliferative activity in colorectal adenocarcinomas. Mod
Petrowsky H, Sturm I, Graubitz O, Kooby AD, Staib-Sebler E,
Gog C et al. Relevance of Ki-67 antigen expression and K-ras
mutation in colorectal liver metastases. E J S O 2001;27:80–7.
.Michael-Robinson MJ, Reid EL, Puride MD, BiemerHuttmann EA, Walsh DM, Pandeeya N, et al. Proliferation
,Apoptosis and Survival in High Level Microsatellite
Instability Sporadic Colorectal Cancer. Clinical Cancer